» Articles » PMID: 25063693

Principles of Targeting Endothelial Cell Metabolism to Treat Angiogenesis and Endothelial Cell Dysfunction in Disease

Overview
Journal EMBO Mol Med
Specialty Molecular Biology
Date 2014 Jul 27
PMID 25063693
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

The endothelium is the orchestral conductor of blood vessel function. Pathological blood vessel formation (a process termed pathological angiogenesis) or the inability of endothelial cells (ECs) to perform their physiological function (a condition known as EC dysfunction) are defining features of various diseases. Therapeutic intervention to inhibit aberrant angiogenesis or ameliorate EC dysfunction could be beneficial in diseases such as cancer and cardiovascular disease, respectively, but current strategies have limited efficacy. Based on recent findings that pathological angiogenesis and EC dysfunction are accompanied by EC-specific metabolic alterations, targeting EC metabolism is emerging as a novel therapeutic strategy. Here, we review recent progress in our understanding of how EC metabolism is altered in disease and discuss potential metabolic targets and strategies to reverse EC dysfunction and inhibit pathological angiogenesis.

Citing Articles

Unravelling the Mechanisms of Oxidised Low-Density Lipoprotein in Cardiovascular Health: Current Evidence from In Vitro and In Vivo Studies.

Thangasparan S, Kamisah Y, Ugusman A, Anuar N, Ibrahim N Int J Mol Sci. 2025; 25(24.

PMID: 39769058 PMC: 11676878. DOI: 10.3390/ijms252413292.


Mechanosensory entities and functionality of endothelial cells.

Mierke C Front Cell Dev Biol. 2024; 12:1446452.

PMID: 39507419 PMC: 11538060. DOI: 10.3389/fcell.2024.1446452.


Brain microvascular endothelial cell metabolism and its ties to barrier function.

Weber C, Moiz B, Clyne A Vitam Horm. 2024; 126():25-75.

PMID: 39029976 PMC: 11756814. DOI: 10.1016/bs.vh.2024.05.002.


Equine Endothelial Cells Show Pro-Angiogenic Behaviours in Response to Fibroblast Growth Factor 2 but Not Vascular Endothelial Growth Factor A.

Finding E, Faulkner A, Nash L, Wheeler-Jones C Int J Mol Sci. 2024; 25(11).

PMID: 38892205 PMC: 11172845. DOI: 10.3390/ijms25116017.


Steady Laminar Flow Decreases Endothelial Glycolytic Flux While Enhancing Proteoglycan Synthesis and Antioxidant Pathways.

Basehore S, Garcia J, Clyne A Int J Mol Sci. 2024; 25(5).

PMID: 38473731 PMC: 10931250. DOI: 10.3390/ijms25052485.


References
1.
Bergers G, Hanahan D . Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008; 8(8):592-603. PMC: 2874834. DOI: 10.1038/nrc2442. View

2.
Manigrasso M, Juranek J, Ramasamy R, Schmidt A . Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab. 2013; 25(1):15-22. PMC: 3877224. DOI: 10.1016/j.tem.2013.08.002. View

3.
Koziel A, Woyda-Ploszczyca A, Kicinska A, Jarmuszkiewicz W . The influence of high glucose on the aerobic metabolism of endothelial EA.hy926 cells. Pflugers Arch. 2012; 464(6):657-69. PMC: 3513600. DOI: 10.1007/s00424-012-1156-1. View

4.
Noghero A, Perino A, Seano G, Saglio E, Lo Sasso G, Veglio F . Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2. Arterioscler Thromb Vasc Biol. 2012; 32(9):2280-8. DOI: 10.1161/ATVBAHA.112.250621. View

5.
van Beijnum J, Dings R, van der Linden E, Zwaans B, Ramaekers F, Mayo K . Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood. 2006; 108(7):2339-48. DOI: 10.1182/blood-2006-02-004291. View